Product Description
AZD5069 is a potent, selective reversible (time and temperature dependent) antagonist of the human CXCR2 receptor. (Sourced from: https://openinnovation.astrazeneca.com/clinical-research/clinical-molecules/azd5069.html)
Mechanisms of Action: CXCR2 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Bronchitis, Chronic|Emphysema|Chronic Obstructive Pulmonary Disease|Asthma|Bronchiectasis|Squamous Cell Carcinoma|Head and Neck Cancer|Coronary Disease|Prostate Cancer
Phase 1: Asthma|Healthy Volunteers|Chronic Obstructive Pulmonary Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01890148 |
D3551C00003 | P1 |
Completed |
Asthma |
2014-08-01 |
2019-03-19 |
Treatments |
|
NCT01735240 |
D3550C00011 | P1 |
Completed |
Asthma |
2013-02-01 |
2019-03-19 |
Treatments |
|
NCT01480739 |
D3550C00017 | P1 |
Completed |
Healthy Volunteers |
2012-07-01 |
2019-03-19 |
Treatments |
|
NCT01332903 |
D3550C00013 | P1 |
Completed |
Healthy Volunteers |
2011-07-01 |
2019-03-19 |
Treatments |
|
NCT01100047 |
JSMAD | P1 |
Completed |
Healthy Volunteers |
2011-02-01 |
2019-03-19 |
Treatments |
|
NCT01083238 |
D3550C00010 | P1 |
Completed |
Chronic Obstructive Pulmonary Disease |
2010-07-01 |
2019-03-19 |
Treatments |
|
NCT01051505 |
D3550C00007 | P1 |
Completed |
Healthy Volunteers |
2010-04-01 |
2019-03-19 |
Treatments |
|
NCT00953888 |
D3550C00001 | P1 |
Completed |
Healthy Volunteers |
2009-12-01 |
2019-03-18 |
||
NCT03177187 |
ACE | P2 |
Terminated |
Prostate Cancer |
2022-09-15 |
52% |
2023-07-14 |
|
2015-002525-19 |
2015-002525-19 | P2 |
Terminated |
Squamous Cell Carcinoma|Head and Neck Cancer |
2020-12-02 |
12% |
2022-03-13 |
Treatments |
NCT02499328 |
D5660C00004 | P2 |
Completed |
Squamous Cell Carcinoma|Head and Neck Cancer |
2020-02-28 |
12% |
2025-11-13 |
|
2016-000775-24 |
CXCR2 inhibition and coronary disease / CICADA | P2 |
Unknown status |
Coronary Disease |
2019-09-29 |
2022-03-13 |
Treatments |
|
NCT01704495 |
NIMBUS | P2 |
Completed |
Asthma |
2014-08-01 |
2019-03-19 |
Treatments |
|
2012-001869-33 |
2012-001869-33 | P2 |
Terminated |
Asthma |
2014-06-23 |
2025-07-02 |
Treatments |
|
2010-021472-28 |
2010-021472-28 | P2 |
Terminated |
Bronchiectasis |
2012-02-10 |
2022-03-13 |
Treatments |
|
NCT01255592 |
STRATUS | P2 |
Completed |
Bronchiectasis |
2012-02-01 |
2019-03-19 |
Treatments |
|
2010-021217-23 |
CIRRUS | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2011-03-22 |
2022-03-13 |
Treatments |
|
NCT01233232 |
CIRRUS | P2 |
Completed |
Chronic Obstructive Pulmonary Disease|Emphysema|Bronchitis, Chronic |
2011-03-01 |
2019-03-19 |
Treatments |